// App-Quantinova.ai

1335 : Outcomes of Patients with Relapsed/Refractory (R/R) B-Cell Acute Lymphocytic Leukemia (ALL) Post Blinatumomab Failure

Researchers

Presenter

  • Jenny Dahl

Principal Investigators

  • Hagop M. Kantarjian

  • Musa Yilmaz

  • Jane Autry

  • Rebecca Garris

  • Elias Jabbour

  • Tapan Kadia

  • Guillermo Garcia-Manero

  • Farhad Ravandi

  • Gautam Borthakur

  • Jorge E. Cortes

  • Alessandra Ferrajoli

  • Koji Sasaki

  • Jad Chahoud

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, Houston, TX

  • The Scott Department of Urology, Baylor College of Medicine, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Blinatumomab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved